Pneumonia in incident dialysis patients - the United States Renal Data System

United States Renal Data System Coordinating Center, Minneapolis, MN 55404, USA.
Nephrology Dialysis Transplantation (Impact Factor: 3.49). 02/2008; 23(2):680-6. DOI: 10.1093/ndt/gfm474
Source: PubMed

ABSTRACT Although clinical experience suggests that pneumonia may occur frequently in dialysis patients, its clinical epidemiology in that group remains poorly defined.
Medicare claims were used to identify pneumonia episodes in 289,210 patients initiating dialysis in the United States between 1996 and 2001 and followed until 31 December 2003.
Mean patient age was 63.8 years; 48.0% had diabetes and 9.6% used peritoneal dialysis as initial therapy. The overall incidence rate was 27.9/100 patient-years (29.0 in haemodialysis patients vs 18.2 in peritoneal dialysis patients, P < 0.0001) and remained relatively constant from year to year. On multivariate analysis, the primary associations of pneumonia [adjusted hazards ratio (AHR) > 1.25 or < 0.80, P < 0.0001] were chronic obstructive pulmonary disease (AHR 1.47), inability to transfer or ambulate (AHR 1.44), haemodialysis as initial therapy (AHR 1.41 vs peritoneal dialysis), age > or = 75 (AHR 1.40 vs 20-44 years), body mass index > or =30 kg/m(2) (AHR 0.77 vs 18.5-24.9 kg/m(2)) and age 0-19 years (AHR 0.61 vs 20-44 years). Survival probabilities after pneumonia were 0.51 at 1 year. Using interval Poisson regression analysis, AHRs were 4.99 (95% confidence interval 4.87-5.12) for death and 3.02 (2.89-3.16) for cardiovascular disease in the initial 6-month interval after pneumonia, declining to 2.12 (1.90-2.37) for death and 1.45 (1.12-1.87) for cardiovascular disease at 5 years.
Common in dialysis patients, pneumonia is an antecedent association of cardiovascular disease and death.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infections are an important cause of morbidity and mortality among patients at all stages of chronic kidney disease. Prevention through vaccination remains the best strategy to minimize the adverse consequences associated with these infectious diseases in this, and all, populations. Unfortunately, patients with chronic kidney disease demonstrate inadequacies of specific immune-cell function that are required for generating a protective vaccine response. Nevertheless, early vaccination of this high-risk population has demonstrated good clinical outcomes during progression to late-stage disease. We review the available evidence linking immune impairment in adult patients with late-stage chronic kidney disease to diminished vaccine responses. We highlight the importance of early vaccination in disease with high risk for development of CKD and novel vaccine approaches in development that may help to address improvement in protective boosting of immunity during late-stage disease.
    Expert Review of Vaccines 01/2014; DOI:10.1586/14760584.2014.874950 · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infections are a major cause of morbidity and mortality among dialysis patients. Dialysis modality has been hypothesized to be a potential immunomodulatory factor. The objective of this study was to determine the influence of the first dialysis modality on the risk for infections on dialysis. Our study was conducted utilizing the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) cohort of incident dialysis patients. Medical records of all patients from two tertiary care university hospitals and three regional hospitals were reviewed using pre-specified criteria. Information about infections was collected from the start of dialysis until death, modality switch, study withdrawal, kidney transplantation or at the end of the study. Age-standardized incidence rates for infections were calculated. Poisson regression analysis was used to calculate adjusted incidence rate ratios (IRRs). In total, 452 patients, of whom 285 started with haemodialysis (HD) and 167 with peritoneal dialysis (PD), were included. The median follow-up time on the first dialysis modality was similar for HD and PD, 1.8 and 2.0 dialysis years, respectively. During the first 6 months, the age-standardized infection incidence rate was higher on HD compared with PD patients (P = 0.02). Overall, PD patients had a higher infection risk [adjusted IRR: 1.65, 95% confidence interval (CI): 1.34-2.03], which could be attributed to a 4-fold increased risk for dialysis technique-related infections. The risk for non-dialysis technique-related infections was lower in PD patients (adjusted IRR: 0.56, 95% CI: 0.40-0.79). Overall, PD patients carry a higher risk for infections. Interestingly, the risk for non-dialysis technique-related infections was higher in HD patients. The links between dialysis modality and the immune system are expected to explain this difference, but future studies are needed to test these assumptions.
    Nephrology Dialysis Transplantation 08/2014; 29(12). DOI:10.1093/ndt/gfu285 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infectious and cardiovascular (CV) complications take a huge toll on Chronic Kidney Disease and End-Stage Renal Disease patients in terms of morbidity and mortality. Infection leads to increased mortality, directly as a result of infectious disease processes and indirectly as a risk factor for cardiovascular disease. Chronic activation with hyporesponsiveness may be the most accurate description of the immune dysfunction in clinical uremia. Risk factors for infection among patients with CKD or ESRD include high burden of coexisting illnesses, malnutrition, immunosuppressive therapy, uremia and anemia. Infections in dialysis patients could be access related or non-access related. Infections in patients with chronic kidney disease & ESRD are associated with poorer outcomes compared with the general population. Preventive strategies for infection in those with CKD and ESRD are not standardized and are underutilized even in developed countries. Creation of an optimally timed arteriovenous access is the most important step for reducing the risk of infections in hemodialysis patients. Despite the evidence of decreased efficacy of various vaccines, this population should be adequately vaccinated.
    10/2012; 1(4):253–258. DOI:10.1016/j.cqn.2012.09.005


Available from